Impact of pharmacotherapy on the incidence of transurethral prostatectomy for benign prostatic hyperplasia and the implications for surgical training

Irish Medical Journal

Volumn 103, Issue 9, 2010, Pages 1-3

  Long, R ^a   Connolly, S ^a   Sweeney, P ^a  

^a MERCY UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DUTASTERIDE; FINASTERIDE; INDORAMIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT;

AGED; ARTICLE; DEMOGRAPHY; DRUG INDUSTRY; GENERAL HOSPITAL; HUMAN; INCIDENCE; IRELAND; MAJOR CLINICAL STUDY; MALE; PRIVATE HOSPITAL; PROSTATE HYPERTROPHY; PUBLIC HEALTH SERVICE; RETROSPECTIVE STUDY; SURGICAL TRAINING; TRANSURETHRAL RESECTION; UROLOGY; DRUG UTILIZATION; UTILIZATION REVIEW;

5-ALPHA REDUCTASE INHIBITORS; ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; DRUG UTILIZATION; HUMANS; IRELAND; MALE; PROSTATIC HYPERPLASIA; RETROSPECTIVE STUDIES; TRANSURETHRAL RESECTION OF PROSTATE;

EID: 78449241254     PISSN: 03323102     EISSN: 03323102     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Marino RA, Mooppan UM, Kim H, Moog FP, Karenberg A, Moll F. History of urethral catheters and their balloons: drainage, anchorage, dilation, and hemostasis The catheter and its use from Hippocrates to Galen. J Endourol 1993;7:89-92.
2. Moog FP, Karenberg A, Moll F. The catheter and its use from Hippocrates to Galen. J Urol 2005;174:1196-8.
3. Hopkins HH. Optical principles of the endoscope. Endoscopy 1976:3-26.
4. Lepor H, Machi G. Comparison of AUA symptom index in unselected males and females between fifty-five and seventy-nine years of age. Urology 1993;42:36-40; discussion -1.
5. Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P. Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group. Lancet 1991;337:1457-61.
6. Lepor H, Auerbach S, Puras-Baez A, Narayan P, Soloway M, Lowe F, Moon T, Leifer G, Madsen P. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992;148:1467-74.
7. Gillenwater JY, Conn RL, Chrysant SG, Roy J, Gaffney M, Ice K, Dias N. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J Urol 1995;154:110-15.
8. Roehrborn CG, Bruskewitz R, Nickel GC, Glickman S, Cox C, Anderson R, Kandzari S, Herlihy R, Kornitzer G, Brown BT, Holtgrewe HL,Taylor A, Wang D, Waldstreicher J. Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes.The PLESS Study Group. Eur Urol 2000;37:528-36.
9. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-98.
10. Roehrborn CG. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. BJU Int 2006;97:734-41.
11. Vela-Navarrete R, Gonzalez-Enguita C, Garcia-Cardoso JV, Manzarbeitia F, Sarasa-Corral JL, Granizo JJ. The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002). BJU Int 2005;96:1045-8.
12. Ball AJ, Feneley RC, Abrams PH. The natural history of untreated "prostatism". Br J Urol 1981;53:613-6.
13. Thomas AW, Cannon A, Bartlett E, Ellis-Jones J, Abrams P. The natural history of lower urinary tract dysfunction in men: minimum 10-year urodynamic follow-up of untreated bladder outlet obstruction. BJU Int 2005;96:1301-6.